Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gynecor, a division of Bostwick Laboratories, has unveiled an advanced laboratory technology, cobas 4800 system, that assists physicians in knowing more about patient's condition and improve treatment.
Subscribe to our email newsletter
Cobas 4800 system, a new analyzer, performs DNA-based tests and will be tested with cobas HPV (Human Papillomavirus) test, a new cervical cancer screening test approved by the FDA.
The test will help doctors to diagnose the presence of HPV 16 or 18 — the two types that cause 70% of cervical cancers along with the 12 other high-risk types in women 30 years and older.
Bostwick Laboratories Molecular Diagnostics director Deloar Hossain said the new technology offers more information to physicians and patients about women at the highest risk for cervical cancer.
"It provides three test results right up front, so the clinician and patient don’t have to wait for the results of one test to see if another is needed,” Hossain added.
The equipment with its simple operating mechanism, is expected to save staff time to concentrate on more clinical trials.
Bostwick chief development officer Rob Shovlin said, "This implementation of the cobas® 4800 system shows Bostwick Laboratories’ and Gynecor’s continued commitment to providing state of the art testing to the field of diagnosing and treating cervical diseases and conditions."